## **Core Concept**
The question revolves around the management of tuberculosis (TB) under the Directly Observed Treatment, Short-course (DOTS) strategy, specifically for a patient who remains sputum smear-positive at the end of the intensive phase of Category I treatment. Category I treatment typically includes an intensive phase with isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by a continuation phase with isoniazid and rifampicin for 4 months.

## **Why the Correct Answer is Right**
For a patient who continues to be sputum smear-positive at the end of the intensive phase (2 months), the standard approach is to extend the intensive phase. This is because the goal is to ensure the patient becomes sputum smear-negative, indicating a significant reduction in bacterial load and infectiousness. Extending the intensive phase, typically by adding another month of the intensive phase drugs, allows more time for the bactericidal effects of these drugs to render the sputum smear-negative.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not provided, but typically, incorrect options might suggest stopping treatment, switching to a completely different regimen without evidence of drug resistance, or moving directly to the continuation phase, which would not be appropriate for a smear-positive patient at this stage.
- **Option B:** Similarly, without the specific content of Option B, one might assume it could suggest an inappropriate action such as adding only one drug or changing to a regimen not indicated for a smear-positive patient at the end of the intensive phase.
- **Option C:** This might suggest a change in treatment approach that doesn't align with standard protocols for handling smear-positive patients at the end of the intensive phase, such as not considering drug resistance testing.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for patients who remain sputum smear-positive at the end of the intensive phase of Category I treatment, the first step is to suspect and then rule out drug resistance, particularly to rifampicin, which would necessitate a change to Category II treatment or another appropriate regimen based on drug susceptibility testing (DST) results. However, before jumping to drug resistance, ensuring adherence and extending the intensive phase as per guidelines is crucial.

## **Correct Answer:** . **extend the intensive phase**